Phase 1-2a Study of EBNA1 Inhibitor, VK-2019, in Patients With Epstein-Barr Virus-positive Nasopharyngeal Cancer

2018-09-28 06:43:12 | BioPortfolio


This study is a First-In-Human clinical trial to assess the safety and preliminary efficacy of VK-2019, an orally administered EBNA1 inhibitor, for the treatment of patients with advanced nasopharyngeal carcinoma.


This is a first-in-human phase 1‑2a dose escalation‑trial of the oral EBNA1 targeting agent VK‑2019 in patients with Epstein-Barr Virus (EBV)-positive recurrent or metastatic nasopharyngeal carcinoma (NPC). Primary objectives include safety profile and PK evaluation to define Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D). Secondary objectives include evaluation of anti‑tumor effect, anti‑EBV activity, food pharmacokinetic (PK) effect and pharmacodynamics.

Once daily dosing using an accelerated titration plan with intrapatient dose escalation is anticipated until Adverse Event (AE) rules are met for stopping the accelerated escalation phase, followed by reversion to a conventional 3+3 escalation plan until MTD has been defined.

There will be extensive blood and urine pharmacokinetic studies performed on all patients.

Extensive safety monitoring will include evaluation of blood counts, blood chemistries, urinalyses, pregnancy testing, EKGs, drug compliance and clinical evaluations focused on adverse event detection and monitoring.

Efficacy evaluation will be per RECIST criteria and pharmacodynamic (PD) evaluation will include blood and tumor tissue evaluations. The tumor tissue biopsies for PD will be limited to a subset of patients at the MTD.

There will be an expansion phase at the MTD, with a food effect sub‑study on a subset of patients treated at MTD.

All treatments will be conducted at the Stanford Cancer Institute (SCI) in Stanford, California. There are limited funds available to support travel to the investigational site. We expect travel to Stanford will be feasible for many patients. An overnight stay in the SCI area may be necessary to collect some PK effect samples.

Study Design


Nasopharyngeal Carcinoma




Stanford University, School of Medicine, Stanford Cancer Institute
United States


Not yet recruiting


The Wistar Institute

Results (where available)

View Results


Published on BioPortfolio: 2018-09-28T06:43:12-0400

Clinical Trials [1307 Associated Clinical Trials listed on BioPortfolio]

Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPC

Nasopharyngeal carcinoma (NPC) is a malignant tumor that originates in nasopharyngeal epithelial cells. It is common in southern China and Southeast Asia, but the incidence rate is low in ...

Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma

The purpose of this study is to test the hypothesis that a combined Immuno-Oncology (IO) strategy would see efficacy in a virally driven cancer like Nasopharyngeal Carcinoma (NPC). Hence, ...

Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma

To study the 2-year PFS (progression-free survival) of patients with stage III nasopharyngeal carcinoma of pretreatment EBV DNA

Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)

To test the therapeutic ratio of additional chemotheray on advanced nasopharyngeal carcinoma.

Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma

To evaluate the efficacy and toxicity of Nimotuzumab combined with VMAT in the treatment of elderly patients with nasopharyngeal carcinoma (> 70 years old), and to provide high-level clini...

PubMed Articles [6669 Associated PubMed Articles listed on BioPortfolio]

Down-regulation of miR-155 promotes apoptosis of nasopharyngeal carcinoma CNE-1 cells by targeting PI3K/AKT-FOXO3a signaling.

Nasopharyngeal carcinoma is one of the common malignant tumors of the ear, nose, and throat in China. Cell apoptosis is expected to be closely related to prognosis. In recent years, with the developme...

Highly expressed CCR7 predicts poor prognosis in locally advanced nasopharyngeal carcinoma.

Nasopharyngeal carcinoma (NC) is a malignant human tumor with a high incidence that occurs on the top and lateral wall of the nasopharynx.

MicroRNA-646 inhibits proliferation and cell cycle progression of nasopharyngeal carcinoma cells by targeting mTOR.

To clarify whether microRNA-646 could regulate the proliferative potential and cell cycle progression of nasopharyngeal carcinoma cells through targeting mammalian target of rapamycin (mTOR). It, ther...

Association of Chemoradiotherapy Regimens and Survival Among Patients With Nasopharyngeal Carcinoma: A Systematic Review and Meta-analysis.

The role of induction chemotherapy (IC) or adjuvant chemotherapy (AC) in the treatment of locoregionally advanced nasopharyngeal carcinoma (NPC) remains controversial.

The evolution of nasopharyngeal carcinoma staging.

The prevalence of nasopharyngeal carcinoma is characterized by an unbalanced distribution: the disease is particularly prevalent in East and Southeast Asia. In this article, we review the evolution of...

Medical and Biotech [MESH] Definitions

A condition in which abnormal cells have not spread outside the duct, lobule, or nipple to other tissues of the breast. There are 3 types of breast carcinoma in situ: DUCTAL CARCINOMA IN SITU; LOBULAR CARCINOMA IN SITU; and PAGET DISEASE OF THE NIPPLE

A transplantable carcinoma of the rat that originally appeared spontaneously in the mammary gland of a pregnant albino rat, and which now resembles a carcinoma in young transplants and a sarcoma in older transplants. (Stedman, 25th ed)

An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.

A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.

A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.

More From BioPortfolio on "Phase 1-2a Study of EBNA1 Inhibitor, VK-2019, in Patients With Epstein-Barr Virus-positive Nasopharyngeal Cancer"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...

Benign Prostatic Hyperplasia (BPH) Erectile Dysfunction Urology Urology is the branch of medicine concerned with the urinary tract and diseases that affect it. Examples include urethritis, urethrostenosis and incontinence. Urology is a su...

Searches Linking to this Trial